CN117897383A - 乌洛地辛盐 - Google Patents

乌洛地辛盐 Download PDF

Info

Publication number
CN117897383A
CN117897383A CN202280050721.6A CN202280050721A CN117897383A CN 117897383 A CN117897383 A CN 117897383A CN 202280050721 A CN202280050721 A CN 202280050721A CN 117897383 A CN117897383 A CN 117897383A
Authority
CN
China
Prior art keywords
salt
luo
glutarate
digoxin
hemi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280050721.6A
Other languages
English (en)
Chinese (zh)
Inventor
韩耀
柴先锋
刘娟
罗秋红
T·梅尔灵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Levorok Immunology Co ltd
Original Assignee
Levorok Immunology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levorok Immunology Co ltd filed Critical Levorok Immunology Co ltd
Publication of CN117897383A publication Critical patent/CN117897383A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280050721.6A 2021-07-20 2022-07-20 乌洛地辛盐 Pending CN117897383A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2110403.9A GB202110403D0 (en) 2021-07-20 2021-07-20 Ulodesine Salt
GB2110403.9 2021-07-20
PCT/EP2022/070369 WO2023001893A1 (en) 2021-07-20 2022-07-20 Ulodesine salt

Publications (1)

Publication Number Publication Date
CN117897383A true CN117897383A (zh) 2024-04-16

Family

ID=77443478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280050721.6A Pending CN117897383A (zh) 2021-07-20 2022-07-20 乌洛地辛盐

Country Status (9)

Country Link
EP (1) EP4373579A1 (enExample)
JP (1) JP2024525254A (enExample)
KR (1) KR20240038017A (enExample)
CN (1) CN117897383A (enExample)
AU (1) AU2022314207A1 (enExample)
CA (1) CA3226849A1 (enExample)
GB (1) GB202110403D0 (enExample)
MX (1) MX2024000936A (enExample)
WO (1) WO2023001893A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553839B2 (en) 2002-08-21 2009-06-30 Industrial Research Limited 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
MX2011009928A (es) * 2009-03-24 2012-03-16 Biocryst Pharm Inc Sales farmaceuticas utiles de 7[(3r, 4r)-3-hidroxi-4-hidroximetil- pirrolidin-1-ilmetil]-3,5-dihidro-pirrol[3,2-d]pirimidin-4-ona.

Also Published As

Publication number Publication date
KR20240038017A (ko) 2024-03-22
GB202110403D0 (en) 2021-09-01
WO2023001893A4 (en) 2023-03-30
CA3226849A1 (en) 2023-01-26
MX2024000936A (es) 2024-06-19
JP2024525254A (ja) 2024-07-11
WO2023001893A1 (en) 2023-01-26
EP4373579A1 (en) 2024-05-29
AU2022314207A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
US12365684B2 (en) Short-acting benzodiazepine salts and their polymorphic forms
CN113454087B (zh) 固体形式的fgfr抑制剂化合物及其制备方法
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
US10246418B2 (en) Crystal form of lenvatinib methanesulfonate salt and preparation method thereof
RU2497820C2 (ru) Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1 - н-бензимидазол-2-ил]хинолин-2(1н)она
JP7855657B2 (ja) フロイミダゾピリジン化合物、多形物質および塩の多形物質の合成方法
CN102358736A (zh) 4-甲基-n-[3-（4-甲基-咪唑-1-基）-5-三氟甲基-苯基]-3-（4-吡啶-3-基-嘧啶-2-基氨基）-苯甲酰胺的晶形
IL320998A (en) A pharmaceutically acceptable salt of a nitrogen-containing heterocyclic compound, its crystalline form and a method for preparing them
KR20240038017A (ko) 울로데신 염
JP6934945B2 (ja) Ｐ２ｘ３アンタゴニストの結晶塩および多形
WO2025012389A1 (en) Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5- morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one, their preparation and their use as erk kinase inhibitors
CN114072406B (zh) Flna-结合化合物及其盐酸盐的固体多晶型物
US12202834B2 (en) Solid state forms of oclacitinib maleate
US20240391933A1 (en) Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
US20240116925A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
CN107344934A (zh) 药物活性物质的固体形式
US12410165B2 (en) Different forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
HK40062038B (en) Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt
WO2023174300A1 (zh) Btk抑制剂的晶型及其酸式盐和其酸式盐的晶型
KR20170036288A (ko) 시타글립틴의 신규염 및 이의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination